DK1137439T4 - Stabilisering af rapamyciner eller rapamycinderivater - Google Patents

Stabilisering af rapamyciner eller rapamycinderivater

Info

Publication number
DK1137439T4
DK1137439T4 DK99959381.7T DK99959381T DK1137439T4 DK 1137439 T4 DK1137439 T4 DK 1137439T4 DK 99959381 T DK99959381 T DK 99959381T DK 1137439 T4 DK1137439 T4 DK 1137439T4
Authority
DK
Denmark
Prior art keywords
rapamycins
stabilization
rapamycin derivatives
rapamycin
derivatives
Prior art date
Application number
DK99959381.7T
Other languages
English (en)
Other versions
DK1137439T3 (da
Inventor
Samuel Petit
Guy Stone
Franacois Navarro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1137439(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1137439T3 publication Critical patent/DK1137439T3/da
Publication of DK1137439T4 publication Critical patent/DK1137439T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DK99959381.7T 1998-12-07 1999-12-06 Stabilisering af rapamyciner eller rapamycinderivater DK1137439T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds
PCT/EP1999/009521 WO2000033878A2 (en) 1998-12-07 1999-12-06 Stabilization of macrolides

Publications (2)

Publication Number Publication Date
DK1137439T3 DK1137439T3 (da) 2007-09-10
DK1137439T4 true DK1137439T4 (da) 2012-03-19

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99959381.7T DK1137439T4 (da) 1998-12-07 1999-12-06 Stabilisering af rapamyciner eller rapamycinderivater

Country Status (38)

Country Link
US (5) US6605613B2 (da)
EP (4) EP1743657A3 (da)
JP (3) JP3805625B2 (da)
KR (2) KR100695834B1 (da)
CN (2) CN1261163C (da)
AR (3) AR026102A1 (da)
AT (1) ATE365051T1 (da)
AU (1) AU759219B2 (da)
BE (1) BE1012869A3 (da)
BR (1) BR9915986A (da)
CA (3) CA2732620C (da)
CO (1) CO4980847A1 (da)
CY (1) CY1106870T1 (da)
CZ (2) CZ303006B6 (da)
DE (1) DE69936352T3 (da)
DK (1) DK1137439T4 (da)
ES (1) ES2288033T5 (da)
FR (1) FR2786771B1 (da)
GB (2) GB9826882D0 (da)
HK (1) HK1038889B (da)
HU (2) HU228939B1 (da)
ID (1) ID29250A (da)
IL (1) IL143092A0 (da)
IT (1) IT1319701B1 (da)
MY (2) MY120594A (da)
NO (2) NO332698B1 (da)
NZ (2) NZ511936A (da)
PE (1) PE20001333A1 (da)
PL (2) PL208854B1 (da)
PT (1) PT1137439E (da)
RU (1) RU2243769C2 (da)
SG (1) SG151072A1 (da)
SI (1) SI1137439T2 (da)
SK (2) SK287325B6 (da)
TR (2) TR200201428T2 (da)
TW (2) TWI248938B (da)
WO (1) WO2000033878A2 (da)
ZA (1) ZA200104360B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1474404A4 (en) 2002-02-13 2006-01-11 Biogal Gyogyszergyar PROCESS FOR EXTRACTION OF A BIOLOGICAL MATERIAL
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
BR0313024A (pt) 2002-07-30 2005-07-12 Wyeth Corp Formulações parenterais contendo um hidroxiéster de rapamicina
WO2004089958A2 (en) * 2003-03-31 2004-10-21 TEVA Gyógyszergyár Részvénytársaság Crystallization and purification of macrolides
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7220357B2 (en) 2003-07-24 2007-05-22 Teva Gyógyszergyár Zártkörúen Múkó´dó´Résvénytársaság Method of purifying macrolides
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
CA2548596A1 (en) * 2003-12-10 2005-06-23 Acrux Dds Pty Ltd. Method of treatment for undesired effect following transdermal or topical drug delivery
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US20060094744A1 (en) * 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
ES2564194T3 (es) 2005-02-09 2016-03-18 Santen Pharmaceutical Co., Ltd. Formulaciones líquidas para el tratamiento de enfermedades o dolencias
CA2630786A1 (en) * 2005-12-07 2007-06-14 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
TW200731967A (en) * 2005-12-20 2007-09-01 Wyeth Corp Control of CCI-779 dosage form stability through control of drug substance impurities
BRPI0707612B8 (pt) * 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
CN103025753A (zh) * 2010-06-07 2013-04-03 泰立克公司 晶体盐酸依泽替米贝非溶剂化物
CN103140494A (zh) * 2010-08-04 2013-06-05 美利奴生命科学有限公司 制备具有抗增殖特性的新的42-o-（杂烷氧基烷基）雷帕霉素化合物的方法
EP2640730B1 (en) 2010-11-19 2019-08-07 Biocon Limited Processes for preparation of everolimus and intermediates thereof
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (da) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
WO2017018433A1 (ja) 2015-07-28 2017-02-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物及びその製造方法
JP6793651B2 (ja) * 2015-08-28 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
EP3351245A4 (en) * 2015-09-18 2019-05-22 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
WO2017204215A1 (ja) 2016-05-27 2017-11-30 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
AU2021242202B2 (en) * 2020-03-27 2024-01-11 Boston Scientific Scimed, Inc. Methods for crystallization of drugs
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
JPH01249651A (ja) † 1988-02-18 1989-10-04 E I Du Pont De Nemours & Co セラミツク／蒸留可能な結合剤組成物
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
JP3108192B2 (ja) * 1991-05-07 2000-11-13 アメリカン・ホーム・プロダクツ・コーポレイション 免疫抑制剤、抗炎症剤または抗真菌剤用ラパマイシンの還元生成物
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
ES2258763T3 (es) 1992-10-13 2006-09-01 Wyeth Carbamatos de rapamicina.
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
CZ292233B6 (cs) * 1995-06-09 2003-08-13 Novartis Ag Deriváty rapamycinu a jejich použití jako léčiv
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
CA2261666C (en) * 1996-07-30 2010-09-14 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
CA2279259A1 (en) 1997-02-04 1998-08-06 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
RU2243769C2 (ru) 2005-01-10
BE1012869A3 (fr) 2001-04-03
EP1743657A3 (en) 2007-03-28
JP5165199B2 (ja) 2013-03-21
DE69936352T3 (de) 2012-05-03
SI1137439T1 (sl) 2008-06-30
TWI248938B (en) 2006-02-11
IL143092A0 (en) 2002-04-21
WO2000033878A3 (en) 2000-11-02
US20050107418A1 (en) 2005-05-19
HK1038889B (zh) 2008-01-25
MY127579A (en) 2006-12-29
JP5043308B2 (ja) 2012-10-10
TR200101416T2 (tr) 2002-01-21
TR200201428T2 (tr) 2002-12-23
PE20001333A1 (es) 2000-12-12
AR026102A1 (es) 2003-01-29
CA2651609A1 (en) 2000-06-15
US20020032213A1 (en) 2002-03-14
EP2279751A2 (en) 2011-02-02
CZ302210B6 (cs) 2010-12-22
FR2786771A1 (fr) 2000-06-09
HK1038889A1 (en) 2002-04-04
FR2786771B1 (fr) 2002-12-27
EP1743657A2 (en) 2007-01-17
NO332698B1 (no) 2012-12-10
ITMI992520A0 (it) 1999-12-02
JP2002531527A (ja) 2002-09-24
NO334612B1 (no) 2014-04-22
TWI270550B (en) 2007-01-11
NO20012424D0 (no) 2001-05-16
PL196627B1 (pl) 2008-01-31
AU759219B2 (en) 2003-04-10
IT1319701B1 (it) 2003-10-27
ES2288033T5 (es) 2012-04-10
CN1876657A (zh) 2006-12-13
CO4980847A1 (es) 2000-11-27
US20090270441A1 (en) 2009-10-29
EP1137439B2 (en) 2011-11-23
KR20010101128A (ko) 2001-11-14
CA2732620A1 (en) 2000-06-15
ES2288033T3 (es) 2007-12-16
CZ20012001A3 (cs) 2001-09-12
US6605613B2 (en) 2003-08-12
US7741338B2 (en) 2010-06-22
AU1657300A (en) 2000-06-26
ID29250A (id) 2001-08-16
AR048073A2 (es) 2006-03-29
CN1261163C (zh) 2006-06-28
US6852729B2 (en) 2005-02-08
US20030191148A1 (en) 2003-10-09
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
EP2269651A3 (en) 2011-03-09
US7297703B2 (en) 2007-11-20
KR100695834B1 (ko) 2007-03-19
CA2351580C (en) 2012-03-20
HU230174B1 (hu) 2015-09-28
HU228939B1 (en) 2013-07-29
SK286688B6 (sk) 2009-03-05
HUP0104489A3 (en) 2004-05-28
DE69936352D1 (de) 2007-08-02
SG151072A1 (en) 2009-06-29
GB9826882D0 (en) 1999-01-27
KR20060096477A (ko) 2006-09-11
PL208854B1 (pl) 2011-06-30
CZ303006B6 (cs) 2012-02-22
EP1137439A2 (en) 2001-10-04
TW200540179A (en) 2005-12-16
CA2351580A1 (en) 2000-06-15
NO20012424L (no) 2001-05-16
SI1137439T2 (sl) 2012-05-31
WO2000033878A2 (en) 2000-06-15
JP2005200429A (ja) 2005-07-28
US20080161334A1 (en) 2008-07-03
ATE365051T1 (de) 2007-07-15
EP1137439B1 (en) 2007-06-20
SK287325B6 (sk) 2010-07-07
PL348333A1 (en) 2002-05-20
EP2279751A3 (en) 2011-02-16
EP2269651A2 (en) 2011-01-05
AR054444A2 (es) 2007-06-27
NO20121113L (no) 2001-05-16
JP2006111637A (ja) 2006-04-27
DE69936352T2 (de) 2008-02-14
NZ527781A (en) 2004-11-26
US7572804B2 (en) 2009-08-11
SK7662001A3 (en) 2001-12-03
NZ511936A (en) 2003-10-31
CA2732620C (en) 2013-08-06
GB9904934D0 (en) 1999-04-28
MY120594A (en) 2005-11-30
JP3805625B2 (ja) 2006-08-02
ZA200104360B (en) 2002-01-16
ITMI992520A1 (it) 2001-06-02
PT1137439E (pt) 2007-09-25
CN1876657B (zh) 2013-01-09
CN1374872A (zh) 2002-10-16
HUP0104489A2 (hu) 2002-03-28
BR9915986A (pt) 2001-09-04

Similar Documents

Publication Publication Date Title
DK1137439T3 (da) Stabilisering af rapamyciner eller rapamycinderivater
DK1384478T3 (da) Antibiotiske sammensætninger indeholdende moxifloxacin til behandling af øjet
DK1117669T3 (da) Antiviruspurinderivater
ID29021A (id) Komposisi galantamina pelepasan terkontrol
PT945132E (pt) Composicao de ibuprofeno
DE69922494D1 (de) Zyklische n-acylamin-derivate
DE69824202D1 (de) Faltbare selbstklebende hängevorrichtung
MA26766A1 (fr) Derives de phenylglycine
PT1073639E (pt) Derivados de quinolina
NO995877D0 (no) Stenter med kontrollert adskillelse
PT1115721E (pt) Derivados de pirimidona
DK1107980T3 (da) Krystallinske former af EtO2C-CH2-(R)Cgl-Aze-Pab-OH
DE60012062D1 (de) Fluorierte Triazinderivate
DE69912590D1 (de) Pde-iv-hemmende pyridin-derivate
IS6127A (is) Ný kristölluð form af makrólíð sýklalyfi
IS5821A (is) Kristalluð form af ósanetant
ATE281436T1 (de) Chinolin-4-yl-derivate
DK0941081T3 (da) Ny anvendelse af creatin
IS5155A (is) Fjölgervingur af zópólrestat mónóhýdrati
DK1001962T3 (da) Fremstilling af avermectinforbindelser
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
DK1159296T3 (da) Fremgangsmåde til fremstilling af cyclo-(Asp-DPhe-NMeVal-Arg-Gly)
NO20006507D0 (no) Propenyl kefalosporinderivater
DK0882722T3 (da) Fremstilling af alpha-tocopherol
FR2778470B1 (fr) Telescope afocal